Open access
Sep 2026
Time-dependent impact of programmed death-ligand 1 expression on early progression and long-term response to first-line osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer.
These findings support risk-adapted therapy; these high-risk subgroups may represent rational candidates for evaluating front-line intensification strategies in prospective clinical trials, whereas osimertinib monotherapy remains appropriate for lower-burden disease, such as postoperative recurrence.
Toshiyuki Sumi, Y. Nagano, O. Honjo et al.
· Lung Cancer · 0 citations